Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.23
ELGX's Cash to Debt is ranked higher than
71% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.04 vs. ELGX: 1.23 )
ELGX' s 10-Year Cash to Debt Range
Min: 1.23   Max: No Debt
Current: 1.23

Equity to Asset 0.50
ELGX's Equity to Asset is ranked higher than
61% of the 301 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. ELGX: 0.50 )
ELGX' s 10-Year Equity to Asset Range
Min: 0.41   Max: 0.96
Current: 0.5

0.41
0.96
F-Score: 3
Z-Score: 5.07
M-Score: -2.36
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -19.75
ELGX's Operating margin (%) is ranked higher than
55% of the 308 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.92 vs. ELGX: -19.75 )
ELGX' s 10-Year Operating margin (%) Range
Min: -237.33   Max: -4.47
Current: -19.75

-237.33
-4.47
Net-margin (%) -21.97
ELGX's Net-margin (%) is ranked higher than
55% of the 308 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.28 vs. ELGX: -21.97 )
ELGX' s 10-Year Net-margin (%) Range
Min: -228.8   Max: 15.84
Current: -21.97

-228.8
15.84
ROE (%) -26.21
ELGX's ROE (%) is ranked higher than
56% of the 297 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.57 vs. ELGX: -26.21 )
ELGX' s 10-Year ROE (%) Range
Min: -56.88   Max: 15.58
Current: -26.21

-56.88
15.58
ROA (%) -12.64
ELGX's ROA (%) is ranked higher than
57% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.93 vs. ELGX: -12.64 )
ELGX' s 10-Year ROA (%) Range
Min: -50.63   Max: 11.48
Current: -12.64

-50.63
11.48
ROC (Joel Greenblatt) (%) -82.72
ELGX's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.68 vs. ELGX: -82.72 )
ELGX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1382.35   Max: -22.12
Current: -82.72

-1382.35
-22.12
Revenue Growth (3Y)(%) 15.40
ELGX's Revenue Growth (3Y)(%) is ranked higher than
93% of the 263 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.60 vs. ELGX: 15.40 )
ELGX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -41.8   Max: 66.8
Current: 15.4

-41.8
66.8
EBITDA Growth (3Y)(%) -7.80
ELGX's EBITDA Growth (3Y)(%) is ranked higher than
61% of the 234 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. ELGX: -7.80 )
ELGX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -50   Max: 73.8
Current: -7.8

-50
73.8
EPS Growth (3Y)(%) -0.70
ELGX's EPS Growth (3Y)(%) is ranked higher than
68% of the 228 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.40 vs. ELGX: -0.70 )
ELGX' s 10-Year EPS Growth (3Y)(%) Range
Min: -51.6   Max: 128.9
Current: -0.7

-51.6
128.9
» ELGX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ELGX Guru Trades in Q1 2014

Paul Tudor Jones 17,562 sh (New)
Pioneer Investments 571,453 sh (+44.97%)
Steven Cohen Sold Out
Jim Simons Sold Out
Ron Baron Sold Out
» More
Q2 2014

ELGX Guru Trades in Q2 2014

Pioneer Investments 585,991 sh (+2.54%)
Paul Tudor Jones Sold Out
» More
Q3 2014

ELGX Guru Trades in Q3 2014

Steven Cohen 216,452 sh (New)
Pioneer Investments 738,560 sh (unchged)
» More
Q4 2014

ELGX Guru Trades in Q4 2014

Steven Cohen Sold Out
Pioneer Investments 689,134 sh (-6.69%)
» More
» Details

Insider Trades

Latest Guru Trades with ELGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Endologix Inc

Meridian Funds Comments on Endologix Inc - Dec 17, 2014

Endologix (ELGX) is a medical device company with products that treat aortic abdominal aneurisms (AAA). Recently the company experienced a decline in sales growth after the conclusion of a clinical trial rollout. We believed the revenue issue was temporary and were very excited about a new product called Nellix that has the potential to more than double Endologix’s market share in AAA procedures. During the quarter, share performance disappointed after the company disclosed that sales would again miss expectations, this time due to an intensifying competitive environment. While management outlined an aggressive response, including product enhancements intended to further improve upon the lowest complication rate in the AAA industry, we have reduced our position until we can gain greater clarity on how effective these efforts will be in the market.

From Meridian Funds (Trades, Portfolio)’ Meridian Contrarian Fund 3Q 2014 Commentary.

Check out Meridian Funds latest stock trades

Top Ranked Articles about Endologix Inc

Meridian Funds Comments on Endologix Inc
Endologix (ELGX) is a medical device company with products that treat aortic abdominal aneurisms (AAA). Recently the company experienced a decline in sales growth after the conclusion of a clinical trial rollout. We believed the revenue issue was temporary and were very excited about a new product called Nellix that has the potential to more than double Endologix’s market share in AAA procedures. During the quarter, share performance disappointed after the company disclosed that sales would again miss expectations, this time due to an intensifying competitive environment. While management outlined an aggressive response, including product enhancements intended to further improve upon the lowest complication rate in the AAA industry, we have reduced our position until we can gain greater clarity on how effective these efforts will be in the market. Read more...

Ratios

vs
industry
vs
history
P/B 9.40
ELGX's P/B is ranked lower than
60% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.00 vs. ELGX: 9.40 )
ELGX' s 10-Year P/B Range
Min: 1.69   Max: 14.14
Current: 9.4

1.69
14.14
P/S 7.67
ELGX's P/S is ranked lower than
69% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.17 vs. ELGX: 7.67 )
ELGX' s 10-Year P/S Range
Min: 1.14   Max: 53.43
Current: 7.67

1.14
53.43
EV-to-EBIT -39.23
ELGX's EV-to-EBIT is ranked higher than
57% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 35.16 vs. ELGX: -39.23 )
ELGX' s 10-Year EV-to-EBIT Range
Min: -178.3   Max: -3.3
Current: -39.23

-178.3
-3.3
Current Ratio 4.99
ELGX's Current Ratio is ranked higher than
90% of the 305 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.61 vs. ELGX: 4.99 )
ELGX' s 10-Year Current Ratio Range
Min: 2.58   Max: 20.25
Current: 4.99

2.58
20.25
Quick Ratio 3.93
ELGX's Quick Ratio is ranked higher than
89% of the 305 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.77 vs. ELGX: 3.93 )
ELGX' s 10-Year Quick Ratio Range
Min: 2.29   Max: 19.04
Current: 3.93

2.29
19.04
Days Inventory 229.03
ELGX's Days Inventory is ranked higher than
57% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 134.93 vs. ELGX: 229.03 )
ELGX' s 10-Year Days Inventory Range
Min: 120.76   Max: 1408.32
Current: 229.03

120.76
1408.32
Days Sales Outstanding 64.58
ELGX's Days Sales Outstanding is ranked higher than
74% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 70.73 vs. ELGX: 64.58 )
ELGX' s 10-Year Days Sales Outstanding Range
Min: 6.64   Max: 125.56
Current: 64.58

6.64
125.56

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 22.50
ELGX's Price/Tangible Book is ranked lower than
54% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.30 vs. ELGX: 22.50 )
ELGX' s 10-Year Price/Tangible Book Range
Min: 0.81   Max: 114.8
Current: 22.5

0.81
114.8
Price/Median PS Value 1.10
ELGX's Price/Median PS Value is ranked higher than
76% of the 341 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. ELGX: 1.10 )
ELGX' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 6.59
Current: 1.1

0.18
6.59
Earnings Yield (Greenblatt) -2.50
ELGX's Earnings Yield (Greenblatt) is ranked higher than
55% of the 304 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.40 vs. ELGX: -2.50 )
ELGX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -3.2   Max: 0
Current: -2.5

-3.2
0

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:RM1.Germany,
Endologix Inc was incorporated in California on March 16, 1992 under the name Cardiovascular Dynamics, Inc. and reincorporated in Delaware in June 1993. The Company develops, manufactures, markets and sells medical devices for the treatment of abdominal aortic aneurysms (AAA). Its main products are intended for the treatment of AAA through minimally-invasive endovascular repair (EVAR) or endovascular sealing ('EVAS'), solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The Company's EVAR products consist of: a cobalt chromium alloy stent covered by polytetrafluoroethylene graft material; and an accompanying delivery system. The Company's EVAS product consists of: bilateral covered stents with endobags; a biocompatible polymer injected into the endobags to seal the aneurysm; and a delivery system and polymer dispenser. All of its products are manufactured, assembled, and packaged at its 60,000 square foot leased facilities in Irvine, California and markets and sells its products in the U.S. and in 11 Western European countries through a direct sales force and network of agents. The Company sells EVAR products through exclusive independent distributors or agents in 14 other European countries, Japan, 9 countries in South America, New Zealand and Mexico. Its main competitors include: Medtronic, Inc., W.L. Gore Inc., and Cook Medical Products, Inc., and new market entrants, TrvVascular, Inc. and Lombard Medical Technologies. The Company is subject to additional licensing and regulatory requirements relating to safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.
» More Articles for ELGX

Headlines

Articles On GuruFocus.com
Meridian Funds Comments on Endologix Inc Dec 17 2014 
Meridian Contrarian Fund 3Q 2014 Commentary Dec 17 2014 
Weekly CFO Sells Highlight: ELGX, LOW, NWS, SBUX, WLP Dec 18 2012 
Endologix Inc Reports Operating Results (10-K) Mar 16 2011 
Endologix Inc Reports Operating Results (10-Q) Nov 08 2010 
Weekly CFO Buys Highlight: FCTOA, GNBT, CTTC, ELGX, ARTC Nov 07 2010 
Endologix Inc Reports Operating Results (10-Q) Jul 30 2010 
Weekly CEO Sells Highlight: Cisco Systems Inc, AmerisourceBergen Corp, PAETEC HOLDING CORP, Endologi May 22 2010 
Endologix Inc (ELGX) CEO John D Mcdermott sells 225,000 Shares May 17 2010 
Endologix Inc Reports Operating Results (10-Q) May 10 2010 

More From Our Partners
Endologix (ELGX) Enters Overbought Territory - Tale of the Tape Apr 1 2015 - ZACKS

More From Other Websites
Endologix to Report First Quarter 2015 Financial Results on April 29, 2015 Apr 13 2015
Endologix (ELGX) Enters Overbought Territory - Tale of the Tape Apr 01 2015
ENDOLOGIX INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers Mar 13 2015
Endologix Announces Chief Financial Officer Transition Mar 12 2015
ENDOLOGIX INC /DE/ Financials Mar 10 2015
10-K for Endologix, Inc. Mar 04 2015
Endologix to Present at the 27th Annual ROTH Conference Mar 03 2015
ENDOLOGIX INC /DE/ Files SEC form 10-K, Annual Report Mar 02 2015
Endologix reports 4Q loss Feb 25 2015
Endologix reports 4Q loss Feb 25 2015
Endologix Inc Earnings Call scheduled for 5:00 pm ET today Feb 25 2015
ENDOLOGIX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition Feb 25 2015
Endologix Reports 10% and 12% Revenue Growth for the Fourth Quarter and Full Year 2014 Feb 25 2015
Q4 2014 Endologix Inc Earnings Release - After Market Close Feb 25 2015
Endologix, Inc. (ELGX), Quest Diagnostics Inc (DGX), The Spectranetics Corporation (SPNC), and More:... Feb 12 2015
Endologix to Report Fourth Quarter and Full Year 2014 Financial Results on February 25, 2015 Jan 26 2015
ENDOLOGIX INC /DE/ Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Nov 25 2014
Endologix to Participate in Two Investor Conferences in December Nov 25 2014
Nellix Clinical Data From the EVAS FORWARD Global Registry Presented at 2014 VEITH Symposium Nov 20 2014
Endologix Completes Patient Enrollment in the Nellix(R) EVAS FORWARD-IDE Clinical Trial Nov 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK